DRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Alpha Tau Medical Ltd (DRTS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The recent approval of the Alpha DaRT device in Japan is a significant positive catalyst, and the stock's technical indicators show bullish momentum. Despite the lack of immediate profitability, the company's financial performance is improving, and analysts have raised their price targets, indicating confidence in the stock's future growth potential.
The MACD histogram is positive and expanding, indicating bullish momentum. The RSI is neutral at 61.055, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above key support levels. Current price is $8.08, with resistance at $8.311 and support at $7.012.
The approval of the Alpha DaRT device in Japan for treating unresectable locally advanced or recurrent head and neck cancer is a major milestone. Analysts have raised the price target from $9 to $12, reflecting increased confidence in the company's prospects.
Revenue remains at $0, indicating the company is still in its growth and development phase.
In Q3 2025, net income improved significantly by 68.78% YoY to -$11.69 million. EPS also improved by 40% YoY to -$0.14. However, revenue and gross margin remain at $0, indicating the company is still pre-revenue.
H.C. Wainwright analyst Yi Chen raised the price target from $9 to $12 and maintained a Buy rating, citing the approval of Alpha DaRT in Japan as a key validation of the platform and a de-risking factor for U.S. clinical development.
